Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MaxFUSE LNPS

Financiado

Cerrado

Engineering lipid nanoparticles to target and escape the endosome, deliver their...

Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapies There is a strong need for personalised genetic medicines for the treatment of advanced breast cancer. LNP-mRNA nanomedicines have already been proven as safe and cost effective in the SARS-CoV-2 vaccines. However, cancer treatmen... ver más

31/05/2029

KTH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KUNGLIGA TEKNISKA HOEGSKOLAN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-03

ERC-2023-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KTH

1.84M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

nanoVAST nanoVAST: a novel, non- viral LNP for precision payload deli... Cerrado

FluoNeeD Fluorinated Lipid Nanoparticles for Gene Delivery and Diagno... 212K€ Cerrado

PCIN-2017-042 NANOTRANSPORTADORES POLIPEPTIDICOS SENSIBLES A LA TEMPERATUR... 138K€ Cerrado

CodeSphere CodeSphere Discovering Therapeutic Nanoparticles by Molecu... 150K€ Cerrado

LIPIRNADO Targeted delivery of lipid nanoparticle-mRNA formulations mo... 223K€ Cerrado

NATPRIME Effective Delivery of Nucleic Acid Therapeutics via Designed... Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2023-11-03
Fecha Fin: 2029-05-31

Líder del proyecto

KUNGLIGA TEKNISKA HOEGSKOLAN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto There is a strong need for personalised genetic medicines for the treatment of advanced breast cancer. LNP-mRNA nanomedicines have already been proven as safe and cost effective in the SARS-CoV-2 vaccines. However, cancer treatments often require (i) repeat dosing (ii) controlled immune response (iii) adaptability to combat drug resistance. There are several LNP-RNA clinical cancer trials ongoing, many of which have reported challenges with toxicity, performance and specificity (off target effects). For an LNP-RNA cancer therapeutic to function, they need to localise in the correct organ, enter the cancer cells and escape the cellular (endosomal) processing pathway to release their RNA cargo. In current LNP-RNA formulations only a small fraction (<10 %) of LNPs successfully escape the endosome. However, these ‘null’ LNPs can still contribute to toxicity which places huge restrictions on their clinical application and performance. The aim of this proposal is to provide mechanistic insight into the endosomal escape of LNPs and use nanoscale engineering to target the endosome and improve LNP endosomal escape. This is particularly relevant in breast cancer as the majority of LNP systems are optimised for liver applications and designed to undergo fusion under ‘healthy’ endosomal conditions. In breast cancer, the composition (lipid, protein) and environment (pH) of the endosome differ significantly between healthy and cancer cells. Objectives: - Use omics approaches to quantify key differences in the endosome in healthy and breast cancer sub type cells and develop breast cancer sub type endosome models - Design LNPs with enhanced fusion to endosomes using (i) lipid composition (ii) protein – protein / lipid interactions (iii) pH mediated fusion - Validate novel LNPs with increased endosomal fusion and lower toxicity for breast cancer treatment

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores